← Oncology Approval Tracker

FDA DECISION ·

Zegfrovy

sunvozertinib · Dizal (Jiangsu) Pharmaceutical

Accelerated approvalNew therapyNon-small cell lung cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

For adults with locally advanced or metastatic NSCLC with an EGFR exon 20 insertion by an FDA-approved test, after progression on or after platinum chemotherapy.

LAMPGEN ANALYSIS

Why it matters

The oral EGFR inhibitor provides a targeted option after platinum for exon 20 insertion disease.

What research teams should watch

Make the exact exon 20 alteration and prior platinum exposure visible in screening records, and prepare counseling on rash and diarrhea.

PRIMARY RECORDS

Sources